Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis
BACKGROUNDSeveral retrospective studies have suggested that immunotherapy, including prednisolone, azathioprine and thymectomy, reduces progression of ocular myasthenia gravis to generalized myasthenia gravis. This study examines the effect of immunotherapy on generalization rates in ocular myasthen...
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-ophthalmology 2003-12, Vol.23 (4), p.251-255 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 255 |
|---|---|
| container_issue | 4 |
| container_start_page | 251 |
| container_title | Journal of neuro-ophthalmology |
| container_volume | 23 |
| creator | Mee, Jared Paine, Mark Byrne, Edward King, John Reardon, Katrina O'Day, Justin |
| description | BACKGROUNDSeveral retrospective studies have suggested that immunotherapy, including prednisolone, azathioprine and thymectomy, reduces progression of ocular myasthenia gravis to generalized myasthenia gravis. This study examines the effect of immunotherapy on generalization rates in ocular myasthenia patients who are acetylcholine receptor (AChR) antibody-positive.
METHODSRetrospective record review of 34 patients from three university-based hospitals with neurology and neuro-ophthalmology services in Australia. In all patients, positive AChR antibodies were recorded, the initial symptoms were purely ocular, and all had at least 2 years of follow-up. The patients who developed generalized myasthenia gravis were compared with those who remained purely ocular.
RESULTSThere were 21 patients who developed generalized myasthenia gravis. Of these 21, only 2 (9.5%) had received prior immunotherapy. Among the 13 patients whose symptoms remained purely ocular, 10 (76.9%) had received prior immunotherapy.
CONCLUSIONSIn this study, most of the patients who progressed from ocular myasthenia to generalized myasthenia had not received prior immunotherapy. This study adds weight to the call for a prospective trial of early immunotherapy in patients with ocular myasthenia. |
| doi_str_mv | 10.1097/00041327-200312000-00002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71440431</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71440431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5022-e852b43480d3e3dd0597badbefbbf6f663a5d17aad5f9bcb94081a00af494cfa3</originalsourceid><addsrcrecordid>eNp1kU2LFDEQhoMo7rr6FyQXvbVWPvrrKIM7LqwsiB4lVCcVpjXdGZPuXcZfb9YZ3YN4SFIUz5sUTxjjAt4I6Nu3AKCFkm0lAZQoG1RlgXzEzkWtmqoWTfO41NBC1YGUZ-xZzt8KoUD2T9mZ0E2jFKhz9vVqmtY5LjtKuD_w6PmNXQMm_vGAuXTnEfk24e2Y-Sdyq6XMN3G-pZTHOPMl8i3NJRrGn-T-zTxnTzyGTC9O5wX7cvn-8-ZDdX2zvdq8u65sXaarqKvloJXuwClSzkHdtwO6gfww-MaXWbF2okV0te8HO_QaOoEA6HWvrUd1wV4f792n-GOlvJhpzJZCwJnimk0rtAatRAG7I2hTzDmRN_s0TpgORoC5V2v-qDV_1Zrfakv05emNdZjIPQRPLgvw6gRgthh8wtmO-YGrVSdlf8_pI3cXw1JEfg_rHSWzIwzLzvzva9Uv-12R-A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71440431</pqid></control><display><type>article</type><title>Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Mee, Jared ; Paine, Mark ; Byrne, Edward ; King, John ; Reardon, Katrina ; O'Day, Justin</creator><creatorcontrib>Mee, Jared ; Paine, Mark ; Byrne, Edward ; King, John ; Reardon, Katrina ; O'Day, Justin</creatorcontrib><description>BACKGROUNDSeveral retrospective studies have suggested that immunotherapy, including prednisolone, azathioprine and thymectomy, reduces progression of ocular myasthenia gravis to generalized myasthenia gravis. This study examines the effect of immunotherapy on generalization rates in ocular myasthenia patients who are acetylcholine receptor (AChR) antibody-positive.
METHODSRetrospective record review of 34 patients from three university-based hospitals with neurology and neuro-ophthalmology services in Australia. In all patients, positive AChR antibodies were recorded, the initial symptoms were purely ocular, and all had at least 2 years of follow-up. The patients who developed generalized myasthenia gravis were compared with those who remained purely ocular.
RESULTSThere were 21 patients who developed generalized myasthenia gravis. Of these 21, only 2 (9.5%) had received prior immunotherapy. Among the 13 patients whose symptoms remained purely ocular, 10 (76.9%) had received prior immunotherapy.
CONCLUSIONSIn this study, most of the patients who progressed from ocular myasthenia to generalized myasthenia had not received prior immunotherapy. This study adds weight to the call for a prospective trial of early immunotherapy in patients with ocular myasthenia.</description><identifier>ISSN: 1070-8022</identifier><identifier>EISSN: 1536-5166</identifier><identifier>DOI: 10.1097/00041327-200312000-00002</identifier><identifier>PMID: 14663303</identifier><identifier>CODEN: JNEOEK</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Disease Progression ; Diseases of striated muscles. Neuromuscular diseases ; Female ; Humans ; Immunotherapy - adverse effects ; Male ; Medical sciences ; Middle Aged ; Myasthenia Gravis - physiopathology ; Myasthenia Gravis - therapy ; Neurology ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Journal of neuro-ophthalmology, 2003-12, Vol.23 (4), p.251-255</ispartof><rights>2003 Lippincott Williams & Wilkins, Inc.</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5022-e852b43480d3e3dd0597badbefbbf6f663a5d17aad5f9bcb94081a00af494cfa3</citedby><cites>FETCH-LOGICAL-c5022-e852b43480d3e3dd0597badbefbbf6f663a5d17aad5f9bcb94081a00af494cfa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf><![CDATA[$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&PDF=y&D=ovft&AN=00041327-200312000-00002$$EPDF$$P50$$Gwolterskluwer$$H]]></linktopdf><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00041327-200312000-00002$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,780,784,4609,27924,27925,64666,65461</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15382293$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14663303$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mee, Jared</creatorcontrib><creatorcontrib>Paine, Mark</creatorcontrib><creatorcontrib>Byrne, Edward</creatorcontrib><creatorcontrib>King, John</creatorcontrib><creatorcontrib>Reardon, Katrina</creatorcontrib><creatorcontrib>O'Day, Justin</creatorcontrib><title>Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis</title><title>Journal of neuro-ophthalmology</title><addtitle>J Neuroophthalmol</addtitle><description>BACKGROUNDSeveral retrospective studies have suggested that immunotherapy, including prednisolone, azathioprine and thymectomy, reduces progression of ocular myasthenia gravis to generalized myasthenia gravis. This study examines the effect of immunotherapy on generalization rates in ocular myasthenia patients who are acetylcholine receptor (AChR) antibody-positive.
METHODSRetrospective record review of 34 patients from three university-based hospitals with neurology and neuro-ophthalmology services in Australia. In all patients, positive AChR antibodies were recorded, the initial symptoms were purely ocular, and all had at least 2 years of follow-up. The patients who developed generalized myasthenia gravis were compared with those who remained purely ocular.
RESULTSThere were 21 patients who developed generalized myasthenia gravis. Of these 21, only 2 (9.5%) had received prior immunotherapy. Among the 13 patients whose symptoms remained purely ocular, 10 (76.9%) had received prior immunotherapy.
CONCLUSIONSIn this study, most of the patients who progressed from ocular myasthenia to generalized myasthenia had not received prior immunotherapy. This study adds weight to the call for a prospective trial of early immunotherapy in patients with ocular myasthenia.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Disease Progression</subject><subject>Diseases of striated muscles. Neuromuscular diseases</subject><subject>Female</subject><subject>Humans</subject><subject>Immunotherapy - adverse effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myasthenia Gravis - physiopathology</subject><subject>Myasthenia Gravis - therapy</subject><subject>Neurology</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>1070-8022</issn><issn>1536-5166</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU2LFDEQhoMo7rr6FyQXvbVWPvrrKIM7LqwsiB4lVCcVpjXdGZPuXcZfb9YZ3YN4SFIUz5sUTxjjAt4I6Nu3AKCFkm0lAZQoG1RlgXzEzkWtmqoWTfO41NBC1YGUZ-xZzt8KoUD2T9mZ0E2jFKhz9vVqmtY5LjtKuD_w6PmNXQMm_vGAuXTnEfk24e2Y-Sdyq6XMN3G-pZTHOPMl8i3NJRrGn-T-zTxnTzyGTC9O5wX7cvn-8-ZDdX2zvdq8u65sXaarqKvloJXuwClSzkHdtwO6gfww-MaXWbF2okV0te8HO_QaOoEA6HWvrUd1wV4f792n-GOlvJhpzJZCwJnimk0rtAatRAG7I2hTzDmRN_s0TpgORoC5V2v-qDV_1Zrfakv05emNdZjIPQRPLgvw6gRgthh8wtmO-YGrVSdlf8_pI3cXw1JEfg_rHSWzIwzLzvzva9Uv-12R-A</recordid><startdate>200312</startdate><enddate>200312</enddate><creator>Mee, Jared</creator><creator>Paine, Mark</creator><creator>Byrne, Edward</creator><creator>King, John</creator><creator>Reardon, Katrina</creator><creator>O'Day, Justin</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200312</creationdate><title>Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis</title><author>Mee, Jared ; Paine, Mark ; Byrne, Edward ; King, John ; Reardon, Katrina ; O'Day, Justin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5022-e852b43480d3e3dd0597badbefbbf6f663a5d17aad5f9bcb94081a00af494cfa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Disease Progression</topic><topic>Diseases of striated muscles. Neuromuscular diseases</topic><topic>Female</topic><topic>Humans</topic><topic>Immunotherapy - adverse effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myasthenia Gravis - physiopathology</topic><topic>Myasthenia Gravis - therapy</topic><topic>Neurology</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mee, Jared</creatorcontrib><creatorcontrib>Paine, Mark</creatorcontrib><creatorcontrib>Byrne, Edward</creatorcontrib><creatorcontrib>King, John</creatorcontrib><creatorcontrib>Reardon, Katrina</creatorcontrib><creatorcontrib>O'Day, Justin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mee, Jared</au><au>Paine, Mark</au><au>Byrne, Edward</au><au>King, John</au><au>Reardon, Katrina</au><au>O'Day, Justin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis</atitle><jtitle>Journal of neuro-ophthalmology</jtitle><addtitle>J Neuroophthalmol</addtitle><date>2003-12</date><risdate>2003</risdate><volume>23</volume><issue>4</issue><spage>251</spage><epage>255</epage><pages>251-255</pages><issn>1070-8022</issn><eissn>1536-5166</eissn><coden>JNEOEK</coden><abstract>BACKGROUNDSeveral retrospective studies have suggested that immunotherapy, including prednisolone, azathioprine and thymectomy, reduces progression of ocular myasthenia gravis to generalized myasthenia gravis. This study examines the effect of immunotherapy on generalization rates in ocular myasthenia patients who are acetylcholine receptor (AChR) antibody-positive.
METHODSRetrospective record review of 34 patients from three university-based hospitals with neurology and neuro-ophthalmology services in Australia. In all patients, positive AChR antibodies were recorded, the initial symptoms were purely ocular, and all had at least 2 years of follow-up. The patients who developed generalized myasthenia gravis were compared with those who remained purely ocular.
RESULTSThere were 21 patients who developed generalized myasthenia gravis. Of these 21, only 2 (9.5%) had received prior immunotherapy. Among the 13 patients whose symptoms remained purely ocular, 10 (76.9%) had received prior immunotherapy.
CONCLUSIONSIn this study, most of the patients who progressed from ocular myasthenia to generalized myasthenia had not received prior immunotherapy. This study adds weight to the call for a prospective trial of early immunotherapy in patients with ocular myasthenia.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>14663303</pmid><doi>10.1097/00041327-200312000-00002</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1070-8022 |
| ispartof | Journal of neuro-ophthalmology, 2003-12, Vol.23 (4), p.251-255 |
| issn | 1070-8022 1536-5166 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71440431 |
| source | MEDLINE; Journals@Ovid LWW Legacy Archive; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Biological and medical sciences Disease Progression Diseases of striated muscles. Neuromuscular diseases Female Humans Immunotherapy - adverse effects Male Medical sciences Middle Aged Myasthenia Gravis - physiopathology Myasthenia Gravis - therapy Neurology Retrospective Studies Treatment Outcome |
| title | Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T18%3A24%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunotherapy%20of%20Ocular%20Myasthenia%20Gravis%20Reduces%20Conversion%20to%20Generalized%20Myasthenia%20Gravis&rft.jtitle=Journal%20of%20neuro-ophthalmology&rft.au=Mee,%20Jared&rft.date=2003-12&rft.volume=23&rft.issue=4&rft.spage=251&rft.epage=255&rft.pages=251-255&rft.issn=1070-8022&rft.eissn=1536-5166&rft.coden=JNEOEK&rft_id=info:doi/10.1097/00041327-200312000-00002&rft_dat=%3Cproquest_cross%3E71440431%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71440431&rft_id=info:pmid/14663303&rfr_iscdi=true |